Drug Profile

LTI 291

Alternative Names: BIA 28-6156/LTI-291; LTI-00291; LTI-291

Latest Information Update: 24 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Lysosomal Therapeutics
Developer BIAL; Lysosomal Therapeutics
Class Amides; Antiparkinsonians; Cyclohexanes; Ethers; Pyrazoles; Pyrimidines; Small molecules
Mechanism of Action Glucosylceramidase stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Parkinson's disease

Most Recent Events

10 Aug 2026 BIAL completes an expanded-access programme for Parkinson disease in USA, Italy, Portugal, Spain, UK (NCT07522606)
24 Jul 2026 BIAL terminates phase-I clinical trials in Parkinson's disease in Hungary (PO) (CTIS2025-520754-11-00)
09 Jun 2026 Discontinued - Clinical-Phase-Unknown for Parkinson's disease in Netherlands (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com